HEPA and PARSE: Systematic discovery of clinically relevant tumor-specific antigens

Qing Wen Xu; Yu Zhang; Xiao Song Wang

doi:10.4161/onci.23249

HEPA and PARSE: Systematic discovery of clinically relevant tumor-specific antigens

Qing Wen Xu, Yu Zhang, Xiao Song Wang

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The effective discovery of tumor-specific antigens (TS As) holds the key for the development of new diagnostic assays and immunotherapeutic approaches against cancer. Here, we discuss our recently developed technologies, HE PA and PARSE, which allow for the systematic identification of TS As, generating a reservoir of immunologically andclinically relevant targets.

Original language	English (US)
Article number	e23249
Journal	OncoImmunology
Volume	2
Issue number	3
DOIs	https://doi.org/10.4161/onci.23249
State	Published - Mar 2013
Externally published	Yes

Keywords

Autoantibody signatures
Gene expression profiling
Immunodiagnosis
Tumor-specific antigen

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.4161/onci.23249

Cite this

@article{00acd520e1634ba1a49df570d9833a75,

title = "HEPA and PARSE: Systematic discovery of clinically relevant tumor-specific antigens",

abstract = "The effective discovery of tumor-specific antigens (TS As) holds the key for the development of new diagnostic assays and immunotherapeutic approaches against cancer. Here, we discuss our recently developed technologies, HE PA and PARSE, which allow for the systematic identification of TS As, generating a reservoir of immunologically andclinically relevant targets.",

keywords = "Autoantibody signatures, Gene expression profiling, Immunodiagnosis, Tumor-specific antigen",

author = "Xu, {Qing Wen} and Yu Zhang and Wang, {Xiao Song}",

year = "2013",

month = mar,

doi = "10.4161/onci.23249",

language = "English (US)",

volume = "2",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "3",

}

TY - JOUR

T1 - HEPA and PARSE

T2 - Systematic discovery of clinically relevant tumor-specific antigens

AU - Xu, Qing Wen

AU - Zhang, Yu

AU - Wang, Xiao Song

PY - 2013/3

Y1 - 2013/3

N2 - The effective discovery of tumor-specific antigens (TS As) holds the key for the development of new diagnostic assays and immunotherapeutic approaches against cancer. Here, we discuss our recently developed technologies, HE PA and PARSE, which allow for the systematic identification of TS As, generating a reservoir of immunologically andclinically relevant targets.

AB - The effective discovery of tumor-specific antigens (TS As) holds the key for the development of new diagnostic assays and immunotherapeutic approaches against cancer. Here, we discuss our recently developed technologies, HE PA and PARSE, which allow for the systematic identification of TS As, generating a reservoir of immunologically andclinically relevant targets.

KW - Autoantibody signatures

KW - Gene expression profiling

KW - Immunodiagnosis

KW - Tumor-specific antigen

UR - http://www.scopus.com/inward/record.url?scp=84886944022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886944022&partnerID=8YFLogxK

U2 - 10.4161/onci.23249

DO - 10.4161/onci.23249

M3 - Article

C2 - 23802073

AN - SCOPUS:84886944022

SN - 2162-4011

VL - 2

JO - OncoImmunology

JF - OncoImmunology

IS - 3

M1 - e23249

ER -

HEPA and PARSE: Systematic discovery of clinically relevant tumor-specific antigens

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this